T4乳腺癌新辅助化疗后重建的安全性:即刻、延迟与不重建的比较
该回顾性队列纳入2007至2019年接受新辅助化疗、乳房切除和术后放疗的269例T4乳腺癌女性,比较即刻重建、延迟重建与不重建的结局。即刻重建与T4a-c及年轻独立相关,T4d患者即刻重建并发症风险高且放疗启动延迟,局部复发累积发生率T4d为16%、T4a-c为2.2%。
要点
- T4d乳腺癌即刻重建并发症风险高(46%),放疗启动常延迟。
- T4d局部复发累积发生率16%,显著高于T4a-c的2.2%。
- 建议乳房切除与重建间隔>18个月可能更安全。
核心结论
- T4乳腺癌即刻重建后,尤其T4d患者,辅助治疗延迟且并发症多,建议乳房切除与重建间隔>18个月。
研究设计与样本
- 回顾性连续队列,纳入2007年1月至2019年12月接受新辅助化疗、乳房切除和术后放疗的T4乳腺癌女性269例。
主要发现
- 269例中位年龄52岁(IQR 45-62),T4d占61%,即刻重建17%、延迟重建15%、不重建68%。
- 即刻重建独立与T4a-c疾病(OR 5.75,95%CI 2.57-12.87,p<0.001)和年轻年龄(OR 0.91,95%CI 0.86-0.94,p<0.001)相关。
- 即刻重建并发症总体22%,T4d患者46%(6/13),不重建总体4.4%,延迟重建7.3%(p<0.001)。
- 即刻重建与术后放疗间隔>8周相关(p<0.001)。
- 中位随访4.2年,首次复发中位时间18个月,组间相似(p=0.13);局部复发累积发生率T4d 16%、T4a-c 2.2%(p<0.001)。
临床怎么用
- T4d乳腺癌患者应谨慎选择即刻重建,充分告知并发症和放疗延迟风险。
- 考虑将重建推迟至乳房切除后>18个月以降低风险。
局限性
- 回顾性设计,样本来自单中心,即刻重建组样本量小(尤其T4d仅13例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite limited evidence regarding its safety, immediate reconstruction (IR) is increasingly offered to women with T4 breast cancer. We compared outcomes after IR, delayed reconstruction (DR), and no reconstruction (NR) in patients treated with neoadjuvant chemotherapy (NAC) and postmastectomy radiation therapy (PMRT) for T4 disease. STUDY DESIGN: We retrospectively identified consecutive women with T4 tumors treated with trimodality therapy from January 2007 through December 2019. Clinicopathologic characteristics, complications requiring reoperation, time to PMRT, and recurrence patterns were compared. The cumulative incidence of local recurrence (LR) was estimated using Kaplan-Meier methods. RESULTS: Of the 269 women identified, the median (IQR) age was 52 (45-62) years; 164 women (61%) had T4d disease. Forty-five women (17%) had IR, 41 (15%) had DR, and 183 (68%) had NR. IR was independently associated with T4a-c disease (odds ratio [OR], 5.75; 95% CI, 2.57-12.87; p < 0.001) and younger age (OR 0.91; 95% CI, 0.86-0.94; p < 0.001). The risk of complications after IR was 22% overall and 46% in T4d patients (6/13), compared with 4.4% overall for NR and 7.3% for DR (p < 0.001). IR was associated with >8-week interval to PMRT (p < 0.001). At a median (range) follow-up of 4.2 (0.2-13) years, the median time to first recurrence was 18 months and was similar between groups (p = 0.13). The cumulative incidence of LR was 16% for T4d disease and 2.2% for T4a-c disease (p < 0.001). CONCLUSIONS: After IR, women with T4 tumors, particularly T4d disease, experienced delayed initiation of adjuvant treatment and substantial morbidity, suggesting that an interval of >18 months between mastectomy and reconstruction is advisable.
引用
- Pawloski KR, Barrio AV, Gemignani ML, et al. Reconstruction in Women with T4 Breast Cancer after Neoadjuvant Chemotherapy: When Is It Safe? J Am Coll Surg. 2021. PMID: 33957258. doi:10.1016/j.jamcollsurg.2021.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。